37.72 -0.02 (-0.05%)
After hours: 6:14PM EST
|Bid||37.72 x 1400|
|Ask||37.80 x 4000|
|Day's Range||37.04 - 37.94|
|52 Week Range||33.97 - 46.47|
|Beta (3Y Monthly)||0.66|
|PE Ratio (TTM)||13.35|
|Earnings Date||Jan 27, 2020 - Jan 31, 2020|
|Forward Dividend & Yield||1.44 (3.89%)|
|1y Target Est||41.45|
A Florida-based foundation is paying $4 million to settle claims it worked with two of the Boston area’s biggest drugmakers to use kickback payments to boost sales of their drugs.
Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.
DOW UPDATE Dragged down by declines for shares of Home Depot and 3M, the Dow Jones Industrial Average is down Wednesday afternoon. The Dow (DJIA) was most recently trading 103 points, or 0.4%, lower, as shares of Home Depot (HD) and 3M (MMM) have contributed to the index's intraday decline.
DOW UPDATE The Dow Jones Industrial Average is down Wednesday afternoon with shares of Home Depot and Apple Inc. seeing the biggest declines for the index. Shares of Home Depot (HD) and Apple Inc. (AAPL) have contributed to the index's intraday decline, as the Dow (DJIA) was most recently trading 179 points, or 0.
DOW UPDATE Shares of 3M and Pfizer are posting losses Wednesday morning, dragging the Dow Jones Industrial Average into negative territory. Shares of 3M (MMM) and Pfizer (PFE) are contributing to the blue-chip gauge's intraday decline, as the Dow (DJIA) was most recently trading 77 points (0.
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced the closing of the exclusive licensing agreement with Pfizer Inc. (PFE) for AKCEA-ANGPTL3-LRx following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act). AKCEA-ANGPTL3-LRx is an investigational antisense therapy discovered by Ionis and being developed to treat patients with certain cardiovascular and metabolic diseases. As previously announced, under terms of the agreement Akcea and Ionis will receive a $250 million upfront license fee, which will be split equally between the two companies.
Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.
For roughly the past decade, our primary goal with the Ultimate Stock-Pickers concept has been to uncover investment ideas that reflect the most recent transactions of our "Ultimate Stock-Pickers" in a timely enough manner for investors to get some value from them. In cross-checking the most current valuation work and opinions of Morningstar's own cadre of stock analysts against the actions of some of the best equity managers in the business, we hope to uncover a few good ideas each quarter that investors can dig into a bit deeper to see if they warrant an investment. With 24 of our Ultimate Stock-Pickers having reported their holdings for the third quarter of 2019, we now have a good sense of the stocks that piqued their interest during the period.
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.2 For full details of indications please see the approved label. “Biosimilars like ABRILADA represent an opportunity to help improve access to important treatment options for patients living with chronic, and often debilitating, inflammatory conditions,” said Richard Blackburn, Global President, Pfizer Inflammation and Immunology. The FDA approval was based on the review of a comprehensive data package, which demonstrated biosimilarity of ABRILADA to the reference product.
Pharmaceutical stocks have been beyond wallflowers in 2019. In fact, some of them, like drug giant Pfizer (PFE) have been right down in the fallen angel category until recently, observes growth stock expert Joe Duarte, editor of In the Money Options.
Immunology drug scheduled to supplant the widely used heart medication Lipitor, tallying cumulative sales of $240 billion Continue reading...
U.S. stocks advanced to fresh record highs to close the week. White House economic advisor Larry Kudlow noted that "short strokes" on a trade deal with China are close to completion and that "the mood music is pretty good" when it comes to finally getting Phase I of the accord signed by both sides.Source: FinViz * The S&P 500 rallied 0.77% * The Dow Jones Industrial Average jumped 0.80% * The Nasdaq Composite advanced 0.73% * Pfizer was among the Dow Jones leaders today and one of several stocks in the index with a gain of around 2%With the trade talks being a familiar theme this week, Treasury yields declined for much of the week on some nibbling at defensive trades by market participants. But bond prices declined today on the positive trade news."Concerns about the chances of the U.S. and China completing a phase-one pact had propelled Treasuries earlier this week, and acted as a headwind to a stock rally that keeps taking American gauges to record highs," according to Bloomberg.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSome decent earnings reports out of the semiconductor space propelled all of the Dow's technology components higher today. It also boosted the Nasdaq Composite to another record close. * 10 Cheap Stocks to Buy Under $10 In late trading, about two-thirds of the Dow's 30 constituents were pointed higher with a handful flirting with gains of 2% or more. Pfizer FunIn news that didn't get much attention, Pfizer (NYSE:PFE) and rival Bristol-Myers Squibb (NYSE:BMY) announced the start of a new stroke prevention study known as Guard-af. This stands for "reducing stroke by screening for undiagnosed atrial fibrillation in elderly individuals."While the companies took some liberties with that acronym, shares of Pfizer were up 2% today, pacing a mini-healthcare resurgence for the Dow today because each of the index's components from that sector traded higher on Friday. Nike Rewards InvestorsI mentioned a couple of times in recent days that Nike (NYSE:NKE) was dealing with rough public relations and the trade wranglings with China are often a headwind for NKE stock. But the shares jumped almost 2% today after the Oregon-based company announced a dividend hike.After the close of U.S. markets Thursday, Nike said it's boosting its quarterly payout 11% to 24.5 cents a share from 22 cents."Nike has consistently delivered strong cash flow and returns for shareholders and today's announcement marks NIKE's 18th consecutive year of increasing dividend payouts," said CEO Mark Parker in a statement.Nike was also quick to point out it initiated a four-year, $15 billion share buyback plan last year. Analysts Rush InYesterday, a sell-side analyst demonstrated some guts by issuing a "sell" rating on Apple (NASDAQ:AAPL). Indeed, that's a rare occurrence and investors were reminded of that today as several analysts that cover Apple were talking bullish on the stock.In fact, three analysts -- from J.P. Morgan, Piper Jaffray, and Wedbush --each raised their price forecasts on Apple today.J.P. Morgan's Samik Chatterjee increased his target on the stock to $290 from $280, while Wedbush's Daniel Ives went to $325 from $300. That's the highest on Wall Street.Ives notes "the combination of a 'super cycle' demand driver between iPhone 11/5G lineup of smartphones and a robust ~$60 billion services platform by FY 2021 will be the linchpins of the Apple growth story and stronger fundamental outlook looking ahead and thus command a higher multiple from current levels in our opinion," in a note cited by Barron's. Optimistic ViewHome Depot (NYSE:HD) is one of the few Dow companies that haven't yet reported earnings for the most recent quarter. But next week, it and rival Lowes (NYSE:LOW) step into the earnings confessional. At least one analyst is expecting Home Depot to get the better of its rival again. * 7 Stocks to Buy With Great Charts Today, Jefferies boosted its price target to $268 from $246 on Home Depot. That company reports on Nov. 19 followed by Lowes the next day. Bottom Line on the Dow Jones TodayAll-time highs are good for obvious reasons, but historical data confirm there are added benefits, namely that highs beget more new highs."So, should an all-time stock market high be cause for concern? Not really. Dating back to 1990, the average market returns over the 3-month, 6-month, and 12-month periods following all-time highs were 3%, 6%, and 13%, respectively," according to State Street.The research suggests there were some bumps along the way and that may be the case again this time around, but for now at least, it looks like the major averages are poised to rally into year end.As of this writing, Todd Shriber did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Silver and Gold Stocks to Buy That Offer Contrarian Upside * 7 Earnings Reports to Watch Next Week * 5 Online Retail Stocks to Buy on the Dip The post Dow Jones Today: Stocks Climb on U.S.-China Trade Developments appeared first on InvestorPlace.
DOW UPDATE The Dow Jones Industrial Average is trading up Friday afternoon with shares of UnitedHealth and Pfizer seeing positive gains for the price-weighted average. The Dow (DJIA) is trading 177 points (0.
The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. ultimately impacts the rate of stroke, compared to usual standard medical care.
U.S. stocks, by any broad market measure, trade at or near all-time highs. But in many ways, it doesn't necessarily feel like it.Source: Shutterstock To be sure, there are pockets of strength. Semiconductor stocks keep moving higher, and a blowout report from Nvidia (NASDAQ:NVDA) should drive further optimism toward that sector. The world's two most valuable stocks, Microsoft (NASDAQ:MSFT) and Apple (NASDAQ:AAPL), continue to rally.But this doesn't feel like a market in which rising tides are lifting all of the proverbial boats. Investors clearly are uncomfortable with the valuations assigned growth stocks. 2019's initial public offerings have mostly struggled. Usually, when broad market indices have reached all-time highs, skeptics are calling the gains a bubble, or something close. The trading within the market at the moment makes such an argument difficult to make.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFriday's big stock charts highlight names who have been left out of the recent broad market rally. Two of the stocks are growth plays whose recent trading has been impacted by newly apparent concerns about valuation. Another shows the lack of investor appetite for 'cheap' stocks in sectors with significant external pressure. * 7 Earnings Reports to Watch Next Week All three are the kinds of names that usually run wild when the market has lost discipline. And so, in their own way, these three big stock charts might suggest that U.S. equities actually have more upside ahead. Snap (SNAP)A recurring theme in this space has been the idea that a market at all-time highs no longer seems to ignore valuation. Snap (NYSE:SNAP) is an epitome of that theme, and its chart suggests that investors need to make a decision: * In the context of the broad market, the weakness in SNAP stock over the past two months makes some sense. "Growth at any price" has been replaced by a demand for real, consistent earnings. Whether it's Uber (NYSE:UBER) and Lyft (NASDAQ:LYFT), cannabis stocks, or social media plays, investors are demanding profitability. In that new market, as I wrote this week, SNAP stock suddenly seems out of place. * Technically, there's still a case for more downside in SNAP stock. A clear downtrend has emerged since SNAP stock failed for a second time to break resistance at $18. The 20-day moving average still can act as resistance, and SNAP is hugging the 50-day moving average in a bid to find near-term direction. * And so SNAP seems like a name that could signal broader market moves. SNAP has rallied sharply from December lows, but still remains expensive relative to revenue. A narrowing wedge formation suggests Snap stock will move sharply once it breaks the current range. The question is in which direction it will go. At the moment, the risk seems to the downside -- but if SNAP can bounce back and climb higher, other growth stocks may well follow. Pfizer (PFE)It would seem to follow that if broad market indices are at all-time highs, and growth stocks are struggling, then value plays would be gaining. But as pharmaceutical giant Pfizer (NYSE:PFE) shows, that's not necessarily the case. Even among so-called cheap stocks, the sector matters, and that might be not good news looking at the second of our big stock charts: * PFE stock seemed set to break out after third-quarter results on Oct. 29. A cheap valuation and raised full-year guidance briefly led the stock higher. But a quick sell-off suggests there simply aren't enough buyers out there to drive near-term strength. * The pullback in PFE stock implies that investors need a real catalyst to jump into the pharmaceutical and biotechnology sectors. Bristol-Myers Squibb (NYSE:BMY) has rallied as investors come around to its acquisition of Celgene (NASDAQ:CELG). Quieter names like PFE and Gilead Sciences (NASDAQ:GILD) have struggled to drive consistent gains. * In that context, it's hard to be too optimistic about PFE stock in the near term. The recent pullback has fallen through 20-, 50-, and 200-day moving averages. Support may hold again at $35, but it might take a change in investor sentiment for PFE stock to again rally before Q4 results arrive next year. Splunk (SPLK)If growth stocks do return to favor, Splunk (NASDAQ:SPLK) might be one of the biggest winners. As the last of Friday's big stock charts shows, SPLK has struggled for most of 2019. But there's a case for the weakness to reverse: * At the moment, SPLK stock looks reasonably weak from a trading standpoint. A downgrade to a "Neutral" rating from little-known Cleveland Research helped send shares down 6.2% on Thursday. That's not the kind of response seen from a stock backed by confident investors. * Of course, that trading on Thursday highlights the potential opportunity here. SPLK stock trades at about nine times revenue and 50x next year's consensus earnings per share estimate. Those aren't multiples that suggest that the stock is cheap. But they are more than reasonable in the context of growth stock valuations at the moment. And with earnings on tap next week, those multiples suggest that SPLK stock can rally off a big report. * That context makes Splunk earnings next week important to the market as a whole. Gains in SPLK stock after earnings might suggest that investors still are willing to pay up for growth. But anything less, and SPLK stock has the potential to plunge through support at $110. In that scenario, SPLK can keep falling -- and other growth stocks might well do the same.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Silver and Gold Stocks to Buy That Offer Contrarian Upside * 7 Earnings Reports to Watch Next Week * 5 Online Retail Stocks to Buy on the Dip The post 3 Big Stock Charts for Friday: Snap, Pfizer and Splunk appeared first on InvestorPlace.
Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?